Adaptive Biotechnologies Corp. (ADPT)
29.04
-0.44
(-1.49%)
USD |
NASDAQ |
Nov 13, 16:00
29.04
0.00 (0.00%)
After-Hours: 19:59
Adaptive Biotechnologies Enterprise Value : 4.881B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 4.881B |
| November 11, 2026 | 4.955B |
| November 10, 2026 | 4.861B |
| November 09, 2026 | 5.007B |
| November 06, 2026 | 4.638B |
| November 05, 2026 | 4.453B |
| November 04, 2026 | 4.433B |
| November 03, 2026 | 4.286B |
| November 02, 2026 | 4.167B |
| October 30, 2026 | 4.422B |
| October 29, 2026 | 4.669B |
| October 28, 2026 | 4.701B |
| October 27, 2026 | 4.587B |
| October 26, 2026 | 4.362B |
| October 23, 2026 | 4.239B |
| October 22, 2026 | 4.062B |
| October 21, 2026 | 4.210B |
| October 20, 2026 | 4.063B |
| October 19, 2026 | 3.987B |
| October 16, 2026 | 3.999B |
| October 15, 2026 | 4.251B |
| October 14, 2026 | 4.257B |
| October 13, 2026 | 4.202B |
| October 12, 2026 | 4.249B |
| October 09, 2026 | 4.398B |
| Date | Value |
|---|---|
| October 08, 2026 | 4.333B |
| October 07, 2026 | 4.364B |
| October 06, 2026 | 4.464B |
| October 05, 2026 | 4.939B |
| October 02, 2026 | 4.698B |
| October 01, 2026 | 4.540B |
| September 30, 2026 | 4.787B |
| September 29, 2026 | 4.650B |
| September 28, 2026 | 4.609B |
| September 25, 2026 | 4.755B |
| September 24, 2026 | 4.777B |
| September 23, 2026 | 4.510B |
| September 22, 2026 | 4.537B |
| September 21, 2026 | 4.505B |
| September 18, 2026 | 4.625B |
| September 17, 2026 | 4.615B |
| September 16, 2026 | 4.475B |
| September 15, 2026 | 4.318B |
| September 14, 2026 | 4.015B |
| September 11, 2026 | 3.923B |
| September 10, 2026 | 3.928B |
| September 09, 2026 | 3.958B |
| September 08, 2026 | 3.946B |
| September 04, 2026 | 3.936B |
| September 03, 2026 | 3.982B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Champions Oncology, Inc. | 71.90M |
| Medpace Holdings, Inc. | 17.79B |
| Avantor, Inc. | 13.81B |
| Personalis, Inc. | 1.565B |
| 10X Genomics, Inc. | 7.271B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.806M |
| Revenue (Quarterly) | 83.90M |
| Total Expenses (Quarterly) | 81.03M |
| EPS Diluted (Quarterly) | 0.0154 |
| Gross Profit Margin (Quarterly) | 74.00% |
| Profit Margin (Quarterly) | 3.34% |
| Earnings Yield | -1.55% |
| Normalized Earnings Yield | -1.169 |